 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...8687888990919293949596...235236» |
- Development of a clinically relevant multi-parametric 3D drug screening assay that enables differentiation of cytotoxic/cytostatic responses and treatment resistant subclones at single-organoid level. (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_1296;
For each patient, we seeded 200 organoids per well (in a 384-well plate) and subsequently treated them with clinically relevant concentrations of FOLFIRINOX, Gemcitabine/Nab-Paclitaxel and the corresponding monotherapies...Conclusion We have successfully developed a novel multi-parametric organoid readout that is able to take the subclonal variance (heterogeneity) of treatment response into account. Furthermore, our data addresses the need for including inter-clonal organoid responses, since this could result in a more accurate prediction of the patient-specific clinical outcome.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Profiling the response to neoadjuvant chemoradiotherapy in locally advance rectal cancer using data-independent acquisition mass spectrometry (DIA-MS) (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_856;
All patients were treated with neoadjuvant chemoradiotherapy (5-FU/Leucovorin) and their response was evaluated using a tumor regression grade (TRG) system...Conclusion The DIA-MS approach offered unprecedented proteome coverage for FFPE samples. The differentially expressed proteins and biological processes constitute interesting findings that hold the potential for improving LARC patient management.
- ||| Onivyde (nanoliposomal irinotecan) / Ipsen
Enrollment open: SIRACUSA: A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (clinicaltrials.gov) - Jun 28, 2022
P1, N=88, Recruiting, Sponsor: Ipsen
The differentially expressed proteins and biological processes constitute interesting findings that hold the potential for improving LARC patient management. Not yet recruiting --> Recruiting
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
🎙️ @rachnatshroff of @UAZCancer and ShaalanBeg of @UTSWcancer discuss #precisionmedicine in pancreatic cancer from #ASCO22 & compelling new data from the FOLFOX, FOENIX-CCA2 & HERB trials on the #ASCODailyNews Podcast https://t.co/hbYuYae3JM #gicsm (Twitter) - Jun 27, 2022
- ||| 5-fluorouracil / Generic mfg.
P3 data, Journal, CINV: Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial. (Pubmed Central) - Jun 25, 2022
P3
The patients were randomized in a 1:1 ratio to the aprepitant group (aprepitant 125 mg orally on day 1, 80 mg on day 2-3) and the dexamethasone group (dexamethasone 10 mg intravenously on day 1, 5 mg on days 2 and 3), both groups with palonosetron 0.25 mg intravenously on day 1...Aprepitant combined with palonosetron is superior to dexamethasone combined with palonosetron in patients who received the MEC regimen mFOLFOX6 in terms of preventing CINV. The National Key R&D Program of China (2019YFC1316000) and the National Natural Science Foundation of China (81974369).
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
Journal, HEOR: Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004. (Pubmed Central) - Jun 24, 2022
P2/3
The overall QOL using the C30SummaryScore was improved after neoCRT, but decreased following rectal resection, returning to basal levels at late evaluation. Fecal incontinence was high after sphincter preservation.
- | Trial completion date, Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 24, 2022
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Fecal incontinence was high after sphincter preservation. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
- ||||| Late-breaking abstract, Video: Our @giconnectInfo expert @ChiaraCrem1 provides her perspective on two late breaking abstracts from #ASCO22. LBA5 Single agent #PD-1 blockade in rectal cancer, LBA1 #panitumumab + #mFOLFOX6 vs #bevacizumab +mFOLFOX6 in #mCRC. Watch the video @: https://t.co/4rK6jByhZQ #MedEd (Twitter) - Jun 24, 2022
- ||||| Clinical: ❓How to treat ERBB2-Positive Esophagogastric Adenocarcinoma? doi:10.1001/jamaoncol.2022.2228 ✅AIO INTEGA, 88 pts, 21 sites 👉 higher efficacy for FOLFOX/trastuzumab/nivolumab compared to trastuzumab/nivolumab/ipilimumab ▶️Keynote-811 OS data awaited @OncoAlert @myESMO (Twitter) - Jun 24, 2022
- |||||| GRANITE / Gritstone bio
Enrollment open, Combination therapy, Checkpoint inhibition, Checkpoint block, Metastases: GRANITE: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 24, 2022
P2/3, N=665, Recruiting, Sponsor: Gritstone bio, Inc.
Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 Not yet recruiting --> Recruiting
- ||| Clinical: Testing is the only way to offer the right treatment to the right patient! Promising ph2 1L trials: FIGHT trial: Bemarituzumab/FOLFOX for FGFR2+ per IHC or amplification FAST trial: Zolbetuximab/EOX for CLD18.2+ per IHC (Twitter) - Jun 24, 2022
- | Imkeldi (imatinib) / Shorla Oncology
Enrollment change, Trial completion date, IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 22, 2022
P3, N=475, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=700 --> 475 | Trial completion date: Jun 2028 --> Mar 2028
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Circulating tumor DNA: We yet to know if ctDNA surveillance plus delayed adjuvant therapy for pts with ctDNA (-) is non-inferior to do FOLFOX (also pts seroconverts will be enrolled cohort B for second randomization)❗️This study will answer many questions plus the additive role of Iri for (+) cohort. (Twitter) - Jun 22, 2022
- | Observational data, Journal: FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. (Pubmed Central) - Jun 22, 2022
First-line FFN and NabGem promote similar clinical outcomes. Second-line FFN should be considered after NabGem.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical protocol, Journal: Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial). (Pubmed Central) - Jun 22, 2022
In this open-label, single-centre (Erasmus Univsersity Medical Center, Rotterdam, Netherlands), single-arm, phase I dose finding study, adult patients with metastatic pancreatic cancer with progressive disease after FOLFIRINOX chemotherapy will receive monocyte-derived DCs loaded with an allogeneic tumour lysate in conjunction with a CD40 agonistic antibody...The results of the trial will be submitted for publication in a peer-reviewed scientific journal. NL9723.
- || 5-fluorouracil / Generic mfg.
Reimbursement, Review, Journal: Association between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database. (Pubmed Central) - Jun 22, 2022
Postoperative time to initiation and duration of AC were associated with survival. Based on our results, initiating AC within 2 months after surgery and administering AC for >3 months can potentially have an OS benefit in patients with stage II-III CRC.
- | irinotecan / Generic mfg.
Journal: Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis. (Pubmed Central) - Jun 22, 2022
Furthermore, we applied the above findings to ameliorate CPT-11-caused colitis in rats by inhibiting SP1 with mithramycin A (MitA) or activating TGR5 using oleanolic acid (OA). Our findings may shed light on the discovery of effective interventions for reducing dose-limiting chemotherapy-induced colitis.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Retrospective data, Journal: A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma. (Pubmed Central) - Jun 22, 2022
FOLFIRINOX is a chemotherapy regimen including oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil (5-FU)...No chemotherapy-induced death was documented. CONCLUSIONS This retrospective study indicated that if dose adjustment and adverse events management are properly administrated, mFOLFIRINOX regimen chemotherapy could result in an improved survival compared with S-1 monochemotherapy for resected PC.
- | 5-fluorouracil / Generic mfg.
Journal: Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients. (Pubmed Central) - Jun 22, 2022
Using Leave-One-Out Cross Validation algorithm and Logistic Regression model, 18 gene signatures were identified as predictive biomarkers for oxaliplatin response. Candidate drugs identified by oxaliplatin response signature-based strategies, including inhibitors targeting c-ABL and Notch pathway, DNA/RNA synthesis inhibitors, and HDAC inhibitors, were demonstrated to potently and effectively increase oxaliplatin sensitivity in the resistant PDOs. PDOs are useful in informing decision-making on oxaliplatin-based chemotherapy and in designing personalized chemotherapy in CRC patients.
- | New P3 trial, Minimal residual disease: Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) (clinicaltrials.gov) - Jun 22, 2022
P3, N=340, Not yet recruiting, Sponsor: Yanhong Deng
- | cisplatin / Generic mfg., gemcitabine / Generic mfg.
Journal: Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience. (Pubmed Central) - Jun 22, 2022
Of the 18 patients enrolled, 10 received Gemcitabine/Cisplatin, while 8 patients received either Gemcitabine monotherapy or Capecitabine or FOLFIRI...One Gemcitabine/Cisplatin patient died at 885 days. Our findings suggest improved overall survival outcomes with Gemcitabine plus Cisplatin as neo-adjuvant treatment with no concomitant radiation compared to non-Gemcitabine/Cisplatin regimens in patients with cholangiocarcinoma prior to liver transplantation.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Trial completion date, Metastases: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) (clinicaltrials.gov) - Jun 22, 2022
P3, N=738, Active, not recruiting, Sponsor: Sun Yat-sen University
Our findings suggest improved overall survival outcomes with Gemcitabine plus Cisplatin as neo-adjuvant treatment with no concomitant radiation compared to non-Gemcitabine/Cisplatin regimens in patients with cholangiocarcinoma prior to liver transplantation. Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Apr 2023
- ||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: LUD2015-005: Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer (clinicaltrials.gov) - Jun 21, 2022
P1/2, N=75, Completed, Sponsor: Ludwig Institute for Cancer Research
Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Apr 2023 Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Jun 2022 | Trial primary completion date: Nov 2022 --> Jun 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: #TumorBoardTuesday #1⃣ ✅Dr. Yoshino🧑🏫the results of the Ph 3 PARADIGM trial ➡️FOLFOX-Pani vs. FOLFOX-Bev for RAS WT left CRC 👉823 Pts 👏OS>with Pani 36.2 vs. 31.3 months 👏ORR also > with Pani 75% vs. 67% 🤔BUT the curves don't separate until 26 months❓ 🔎Abstract #LBA1 (Twitter) - Jun 21, 2022
- || onvansertib (PCM-075) / Cardiff Oncology
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (clinicaltrials.gov) - Jun 21, 2022
P1b/2, N=100, Recruiting, Sponsor: Cardiff Oncology
Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Jun 2022 | Trial primary completion date: Nov 2022 --> Jun 2022 Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Dec 2023
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Trial completion date, Trial primary completion date, Metastases: NCI-2018-02122: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin (clinicaltrials.gov) - Jun 21, 2022
P2, N=37, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Dec 2023 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Trial completion date, Combination therapy, Metastases: FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (clinicaltrials.gov) - Jun 21, 2022
P1/2, N=13, Active, not recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023 Recruiting --> Active, not recruiting | N=87 --> 13 | Trial completion date: Mar 2025 --> Oct 2022
- | leucovorin calcium / Generic mfg.
Journal: Biological Characterization and Antimicrobial Bioactives of Mycelium Extracts from Medicinal Mushrooms Phellinus linteus and Pleurotus albidus (Agaricomycetes). (Pubmed Central) - Jun 21, 2022
Taking these findings into consideration, P. albidus and Ph. linteus might be used as sources of bioactive molecules for the development of novel drugs or nutraceuticals, contributing to the improvement of public health.
- | methotrexate / Generic mfg., cytarabine / Generic mfg.
Journal: Upper gastrointestinal bleeding secondary to toxicity by anthracyclines, citarabine and methotrexate in patient with acute lymphoblastic leukemia. (Pubmed Central) - Jun 19, 2022
Given the multiplicity of lesions, medical treatment with high doses of folinic acid, intravenous omeprazole, and transfusion of blood products was decided, with favorable evolution of the gastrointestinal bleeding. However, the patient died of respiratory infection.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Microsatellite instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. (Pubmed Central) - Jun 19, 2022
However, the patient died of respiratory infection. Conversion surgery following pembrolizumab monotherapy has a potential utility for the treatment of MSI-high gastric cancer.
- mitomycin / Generic mfg.
Mitomycin-C associated Posterior Reversible Leukoencephalopathy syndrome (PRES) (Virtual Platform - Poster section) - Jun 17, 2022 - Abstract #Euroanaesthesia2022Euroanaesthesia_622;
PRES is characterized by non-specific neurological symptoms. In the postoperative period, it should be considered when common causes are ruled out.This syndrome is usually reversible after supportive care.
- | NN1213 / Novo Nordisk
Trial completion date, Metastases: CONKO-007: Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (clinicaltrials.gov) - Jun 16, 2022
P3, N=830, Active, not recruiting, Sponsor: University of Erlangen-N
In the postoperative period, it should be considered when common causes are ruled out.This syndrome is usually reversible after supportive care. Trial completion date: Apr 2022 --> Aug 2026
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
However, have seen sustained cCR for 25/5 alone (no chemo) and 25/5 with 2 cycles of FOLFOX! As with many aspects of oncology (and life) better selection criteria may result in improved outcomes. @AndreaCercek NEJM paper a prime example of this https://t.co/RMTFxiMsqp (Twitter) - Jun 15, 2022
- | Enrollment change, Trial withdrawal, Metastases: FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study (clinicaltrials.gov) - Jun 15, 2022
P2, N=0, Withdrawn, Sponsor: Samsung Medical Center
Trial completion date: Apr 2022 --> Aug 2026 N=38 --> 0 | Unknown status --> Withdrawn
- | vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: MP-PDAC-01: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - Jun 15, 2022
P1b, N=36, Recruiting, Sponsor: Joon Oh Park
N=38 --> 0 | Unknown status --> Withdrawn Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Sep 2020 --> Dec 2022
- || Clinical, Journal: Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Jun 15, 2022
In this comparative effectiveness cohort study, FOLFIRINOX was associated with improved survival of approximately 2 months compared with gemcitabine plus nab-paclitaxel and was also associated with fewer posttreatment complications. A randomized clinical trial comparing these first-line treatments is warranted to test the survival and posttreatment hospitalization (or complications) benefit of FOLFIRINOX compared with gemcitabine plus nab-paclitaxel.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Tumor Mutational Burden, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma. (Pubmed Central) - Jun 15, 2022
She had recurrence at 9 months and started pembrolizumab (programmed cell death protein 1, or PD-1receptor antibody) for tumour mutational burden of 10 muts/Mb...Leptomeningeal carcinomatosis was diagnosed. She began palliative radiation but died at 11 months from initial diagnosis.
- || Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead, sotigalimab (PYX-107) / Pyxis Oncology
New P1/2 trial, Metastases: Switch Maintenance in Pancreatic (clinicaltrials.gov) - Jun 15, 2022
P1/2, N=46, Not yet recruiting, Sponsor: James Cleary, MD, PhD
- | Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
Trial completion date, Combination therapy, Metastases: Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 14, 2022
P1/2, N=43, Active, not recruiting, Sponsor: Aadi Bioscience, Inc.
She began palliative radiation but died at 11 months from initial diagnosis. Trial completion date: Dec 2023 --> Dec 2022
- || TTX-030 / AbbVie, Trishula Therap
Enrollment closed, Metastases: ELTIVATE: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Jun 14, 2022
P1, N=185, Active, not recruiting, Sponsor: Trishula Therapeutics, Inc.
Trial completion date: Dec 2023 --> Dec 2022 Recruiting --> Active, not recruiting
- || Clinical data, Journal: The Evolution of Clinical Outcomes In Metastatic Pancreatic Adenocarcinoma: A 10-Year Experience At a Tertiary Referral Center. (Pubmed Central) - Jun 14, 2022
Recent studies have demonstrated survival benefits for FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) and Gem/nab-P (gemcitabine/nab-paclitaxel) over gemcitabine...Age, ECOG-Performance status >1, serum albumin, neutrophil-lymphocyte ratio, and platelets-to-lymphocyte ratio were independent predictors of better OS. In this study of real-world data, the median OS and PFS for all patients with mPDAC was equivalent before and after incorporating newer treatment regimens into the clinical practice.
- || nisevokitug (NIS793) / Novartis
New P1 trial: FOLFIRINOX + NIS793 in Pancreatic Cancer (clinicaltrials.gov) - Jun 14, 2022
P1, N=50, Not yet recruiting, Sponsor: Colin D. Weekes, M.D.
- | Journal: Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. (Pubmed Central) - Jun 14, 2022
Radiological response alone was not a reliable indicator of successful conversion surgery. Patients who underwent conversion surgery had significantly better survival and thus highlighted the importance of surgical exploration in all patients who did not have progressive disease after induction chemotherapy.
- | Avastin (bevacizumab) / Roche
Journal, Combination therapy: Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer. (Pubmed Central) - Jun 14, 2022
Bevacizumab/FOLFIRI with G-NLC as first-line chemotherapy in patients with colorectal cancer with unresectable metastases presented comparable long-term survival outcomes with acceptable toxicity outcomes. Additional randomized controlled studies are needed to establish definitive conclusions regarding this new regimen for metastatic colorectal cancer.
- ||||| Clinical: NOW OPEN @RutgersCancer: “Panit7156: Phase II Pilot Study of FOLFOXIRI plus Panitumumab in Metastatic RAS Wild-Type, Left-Sided Colorectal Cancer.” #ClinicalTrial @HH_Oncodr @RWJBarnabas https://t.co/qlR11ep71l (Twitter) - Jun 14, 2022
- | leucovorin calcium / Generic mfg.
Trial completion date: PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer (clinicaltrials.gov) - Jun 13, 2022
P=N/A, N=48, Active, not recruiting, Sponsor: Vastra Gotaland Region
Additional randomized controlled studies are needed to establish definitive conclusions regarding this new regimen for metastatic colorectal cancer. Trial completion date: Jan 2022 --> Dec 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Head-to-Head, Circulating tumor DNA: 3️⃣ I think, just reducing chemotherapy should not be endpoint of ctDNA trials moving forward as we try to deliver ajd tx more precisely to avoid both OVER and UNDER treatment❗️ ✳️T3N0 only with superiority design by use of FOLFOX would be more exciting and convincing for me‼️ (Twitter) - Jun 13, 2022
- ||| ASP3082 / Astellas
Enrollment open: 3082-CL-0101: A Study of ASP3082 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - Jun 13, 2022
P1, N=136, Recruiting, Sponsor: Astellas Pharma Inc
Trial completion date: Jan 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- ||| ASP2138 / Astellas
Enrollment open, Monotherapy, IO biomarker: A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov) - Jun 13, 2022
P1, N=240, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting